ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Ross Retires From Bristol-Myers, Forms Own Consulting Service; Obey Wins Key Post

April 1, 1994

DCT Concepts Approved

October 11, 1985

WETA Relents Will Air Documentary

April 10, 1987

In Brief: Panel To Meet In Chicago Dec. 15; Rosenberg Picks Up Another Famous Patient; Obey Honored

October 17, 1986

Interview: “People don’t understand Clinical Trials.

September 5, 1997

In Brief: Lasker Foundation Will Not Make 1990 Awards; Michigan Cancer Elects Fischer Vice Chairman

March 2, 1990